SIGA Technologies Inc. (SIGA)
SIGA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.08
-2.53% on the day
Market cap
$221.3M
Micro cap
Revenue · 2025
$94.6M
-31.8% on 2024
Net income · 2025
$23.3M
24.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | SIGA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001010086 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $94.6M |
| Net income | $23.3M |
| Operating income | $23.7M |
| Net margin | 24.6% |
| Operating margin | 25.1% |
| Revenue growth | -31.8% |
| Cash | $155.0M |
| Total assets | $219.5M |
| P/E (computed) | 9.5× |
| P/S (computed) | 2.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document SIGA TECHNOLOGIES, INC 424B3 11-2-2016 | 424B3 | 2016-11-02 |
| Latest annual report FORM 10-K | 10-K | 2026-03-10 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy | DEFA14A | 2026-05-08 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PYXS | Pyxis Oncology Inc. | $1.85 | -7.96% | $221.2M |
| KROS | Keros Therapeutics Inc. | $11.23 | -3.27% | $222.7M |
| SLGL | Sol-Gel Technologies Ltd. | $68.30 | -5.66% | $223.6M |
| LRMR | Larimar Therapeutics Inc. | $2.16 | -14.63% | $224.4M |
| NATR | Nature's Sunshine Products Inc. | $12.76 | +0.39% | $224.5M |
| MGNX | MacroGenics Inc. | $3.42 | -8.06% | $217.9M |
| ADCT | ADC Therapeutics SA Common Shares | $1.70 | -8.60% | $217.0M |
| ZNTL | Zentalis Pharmaceuticals Inc. | $2.40 | -4.76% | $227.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier